XML 221 R83.htm IDEA: XBRL DOCUMENT
v3.20.1

Basis of Presentation (Details) € in Thousands, $ in Thousands |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |  |  |  |  |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Dec. 03, 2019 EUR (€) item | Jul. 24, 2019 EUR (€) shares | Jul. 23, 2019 | Jan. 26, 2018 USD ($) | Jan. 12, 2018 EUR (€) | Jul. 24, 2017 EUR (€) | Jul. 31, 2019 EUR (€) | Apr. 30, 2019 | Mar. 31, 2019 shares | Sep. 30, 2018 EUR (€) | Oct. 31, 2017 EUR (€) | Dec. 31, 2017 | Dec. 31, 2019 EUR (€) shares | Dec. 31, 2018 EUR (€) | Dec. 31, 2017 EUR (€) | Apr. 16, 2019 EUR (€) item | Dec. 28, 2018 USD ($) | Aug. 01, 2018 USD ($) | Mar. 19, 2018 EUR (€) | Oct. 11, 2017 EUR (€) | Jan. 31, 2017 USD ($) | May 11, 2016 USD ($) Center item | May 11, 2016 EUR (€) Center item
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share of Profit (Loss) of Associates and Joint Ventures Accounted for Using Equity Method, Excluding Impairment Loss |  |  |  |  |  |  |  |  |  |  |  |  | € 8,972 |  |  |  |  |  |  |  |  |  |
Consideration Received in Shares | shares |  |  |  |  |  |  |  |  | 1,766,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase in other current financial asset |  |  |  |  |  |  |  |  |  |  |  |  | 1,717,000 |  |  |  |  |  |  |  |  |  |
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity |  |  |  |  |  |  |  |  |  |  |  |  | 1,716,147 | € 465,548 | € (389) |  |  |  |  |  |  |  |
Increase (decrease) through changes in ownership interest on non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  | 1,511,000 |  |  |  |  |  |  |  |  |  |
Gains from change in contractual right value |  |  |  |  |  |  |  |  |  |  |  |  | 1,000 |  |  |  |  |  |  |  |  |  |
Other current assets |  |  |  |  |  |  |  |  |  |  |  |  | 58,111 | 42,344 |  |  |  |  |  |  |  |  |
Non-controlling interests |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity |  |  |  |  |  |  |  |  |  |  |  |  | 1,517,180 | € 469,010 | € (43) |  |  |  |  |  |  |  |
Reserves |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity |  |  |  |  |  |  |  |  |  |  |  |  | 227,000 |  |  |  |  |  |  |  |  |  |
Translation differences |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity |  |  |  |  |  |  |  |  |  |  |  |  | € (22,009) |  |  |  |  |  |  |  |  |  |
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Minority shareholders interest |  |  |  |  |  |  |  |  |  |  |  |  | 45.00% |  |  |  |  |  |  |  |  |  |
Shanghai RAAS Blood Products, Co. Ltd. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Proportion of ownership interest in associate |  |  |  |  |  |  |  |  | 26.20% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Other current assets |  |  |  |  |  |  |  |  |  |  |  |  | € 12,000 |  |  |  |  |  |  |  |  |  |
Shanghai RAAS Blood Products, Co. Ltd. | Grifols Diagnostics Solutions, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares to be delivered | shares |  |  |  |  |  |  |  |  | 90 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Economic rights (as a percent) |  |  |  |  |  |  |  |  | 45.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Biotest Us Corporation and Haema AG |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration for sale of subsidiary | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 538,014 |  |  |  |  |  |
Biotest US Corporation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |  |
Consideration transferred | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 286,454 |  |  |  |  |
Haema, AG |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100.00% |  |  |  |
Consideration transferred |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 220,191 |  |  |  |
Goetech, LLC. ("MedKeeper") |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) |  |  |  | 54.76% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Share capital increase | $ |  |  |  | $ 98,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Aigues Minerals de Vilajuiga, S.A |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred |  |  |  |  | € 550 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Grifols Malaysia Sdn Bhd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  | 30.00% |  |  |  |  |  |  |  |  |  |
Grifols (Thailand) Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of classes of shares | shares |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |
Interstate Blood Bank, Inc., Bio-Blood Components, Inc. and Plasma Biological Services, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 100,000 | € 88,215
Call option price | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |
Agreed payment amount for call option |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000 | € 9,007
Interstate Blood Bank, Inc |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) |  |  |  |  |  |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49.19% | 49.19%
Bio Blood Components Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 48.97% | 48.97%
Plasma Biological Services, LLC. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 48.90% | 48.90%
Number of plasma collection centers | Center |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 26 | 26
Number of blood donation centers | Center |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9 | 9
Number of laboratories | item |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1 | 1
Kiro Grifols S.L (formerly Kiro Robotics S.L) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) |  |  |  |  |  | 90.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  | 40.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration transferred |  |  |  |  |  | € 12,800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Araclon Biotech , S.L |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) | 75.10% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of share capital increases | item | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |  |
First share capital increase |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 16,800 |  |  |  |  |  |  |
Second share capital increase | € 5,900 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Progenika Biopharma, S.A. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership in subsidiary (as a percent) |  | 100.00% | 99.99% |  |  |  |  |  |  |  |  | 90.23% |  |  |  |  |  |  |  |  |  |  |
Increase (decrease) through changes in ownership interests in subsidiaries that do not result in loss of control, equity |  |  |  |  |  |  |  |  |  |  | € (374,000) |  |  |  |  |  |  |  |  |  |  |  |
Share capital increase |  |  |  |  |  |  | € 4 |  |  | € 4,333 |  |  |  |  |  |  |  |  |  |  |  |  |
Cash paid |  | € 4 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Number of shares acquired | shares |  | 33 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Progenika Biopharma, S.A. | Grifols Diagnostics Solutions, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Ownership interest acquired (as a percent) |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0.98% |  |  |
Cash paid |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | € 644 |  |  |
Hologic acquisition |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Cash paid | $ |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,865,000 |  |
Grifols Diagnostics Solutions, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Basis of presentation |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Economic rights (as a percent) |  |  |  |  |  |  |  |  | 55.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Voting rights (as percent) |  |  |  |  |  |  |  |  | 60.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |
Consideration Received in Shares | shares |  |  |  |  |  |  |  |  |  |  |  |  | 1,766,000,000 |  |  |  |  |  |  |  |  |  |

X
- Definition The amount of agreed payment amount for call option under a business combination transaction. + References No definition available. + Details
Name: | grfs_CallOptionAgreedPaymentAmount
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The price of the call option entered into by the company in a business combination transaction. + References No definition available. + Details
Name: | grfs_CallOptionPrice
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of consideration received on sale of subsidiaries. + References No definition available. + Details
Name: | grfs_ConsiderationOnSaleOfSubsidiary
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Number of shares to be received in exchange of shares as per the share exchange agreement. + References No definition available. + Details
Name: | grfs_ConsiderationReceivedInShares
Namespace Prefix: | grfs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes of the table. + References No definition available. + Details
Name: | grfs_DisclosureOfBasisOfPresentationLineItems
Namespace Prefix: | grfs_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of first share capital increase. + References No definition available. + Details
Name: | grfs_FirstShareCapitalIncrease
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Gains on change in ownership interest in subsidiaries which do not result in loss of control. + References No definition available. + Details
Name: | grfs_GainsFromChangeInContractualValueRights
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of increase (decrease) in other current financial assets due to change in ownership interest in subsidiary which do not result in loss of control. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseInOtherCurrentFinancialAssets
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Increase (decrease) through changes in ownership to non-controlling interests. + References No definition available. + Details
Name: | grfs_IncreaseDecreaseThroughChangesInOwnershipInterestsNoncontrollingInterests
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the number of blood donation centers. + References No definition available. + Details
Name: | grfs_NumberOfBloodDonationCenters
Namespace Prefix: | grfs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of classes of shares. + References No definition available. + Details
Name: | grfs_NumberOfClassesOfShares
Namespace Prefix: | grfs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of laboratories. + References No definition available. + Details
Name: | grfs_NumberOfLaboratories
Namespace Prefix: | grfs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition Represents the number of plasma collection centers. + References No definition available. + Details
Name: | grfs_NumberOfPlasmaCollectionCenters
Namespace Prefix: | grfs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of share capital increases carried out by the company. + References No definition available. + Details
Name: | grfs_NumberOfShareCapitalIncreases
Namespace Prefix: | grfs_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | instant

X
- Definition The number of shares acquired in a business combination. + References No definition available. + Details
Name: | grfs_NumberOfSharesAcquired
Namespace Prefix: | grfs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of shares to be delivered as per the shares exchange agreement. + References No definition available. + Details
Name: | grfs_NumberOfSharesToBeDelivered
Namespace Prefix: | grfs_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition The percentage of economic rights contributed in an acquisition. + References No definition available. + Details
Name: | grfs_PercentageOfEconomicRightsContributed
Namespace Prefix: | grfs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition It represents the Percentage Of Minority Shareholders Interest. + References No definition available. + Details
Name: | grfs_PercentageOfMinorityShareholdersInterest
Namespace Prefix: | grfs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of the economic rights in an associate held by the entity. + References No definition available. + Details
Name: | grfs_ProportionOfEconomicRightsHeldInAssociate
Namespace Prefix: | grfs_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of second share capital increase. + References No definition available. + Details
Name: | grfs_SecondShareCapitalIncrease
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The entity's share of the profit (loss) of associates and joint ventures accounted for using the equity method, excluding impairment loss. + References No definition available. + Details
Name: | grfs_ShareOfProfitLossOfAssociatesAndJointVenturesAccountedForUsingEquityMethodExcludingImpairmentLoss
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Subsidiaries, increased capital. + References No definition available. + Details
Name: | grfs_SubsidiariesIncreasedCapital
Namespace Prefix: | grfs_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The fair value, at acquisition date, of the consideration transferred in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph f -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_AcquisitiondateFairValueOfTotalConsiderationTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph f -Clause i -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_CashTransferred
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The increase (decrease) in equity through changes in ownership interests in subsidiaries that do not result in loss of control. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 106 -Subparagraph d -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_106_d_iii&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_IncreaseDecreaseThroughChangesInOwnershipInterestsInSubsidiariesThatDoNotResultInLossOfControl
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets] + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name IAS -Number 1 -IssueDate 2019-01-01 -Paragraph 55 -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=1&code=ifrs-tx-2019-en-r&anchor=para_55&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_OtherCurrentAssets
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2019-01-01 -Paragraph B64 -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B -URIDate 2019-03-27 + Details
Name: | ifrs-full_PercentageOfVotingEquityInterestsAcquired
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of ownership interest in a subsidiary attributable to the entity. [Refer: Subsidiaries [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 19B -Subparagraph c -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_19B_c&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfOwnershipInterestInSubsidiary
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition The proportion of the voting rights in an associate held by the entity. [Refer: Associates [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 17 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_17_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name IAS -Number 27 -IssueDate 2019-01-01 -Paragraph 16 -Subparagraph b -Clause iii -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IAS&num=27&code=ifrs-tx-2019-en-r&anchor=para_16_b_iii&doctype=Standard -URIDate 2019-03-27 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 12 -IssueDate 2019-01-01 -Paragraph 21 -Subparagraph a -Clause iv -URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2019-en-r&anchor=para_21_a_iv&doctype=Standard -URIDate 2019-03-27 + Details
Name: | ifrs-full_ProportionOfVotingPowerHeldInAssociate
Namespace Prefix: | ifrs-full_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_NoncontrollingInterestsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_RetainedEarningsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=grfs_ShanghaiRaasBloodProductsCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_OwnershipAxis=grfs_GrifolsDiagnosticsSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInAssociatesAxis=grfs_ShanghaiRaasBloodProductsCo.LtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=grfs_GrifolsDiagnosticsSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_BiotestUsCorporationAndHaemaAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_BiotestUsCorporationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_HaemaAgMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GoetechLlc.AcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_AiguesMineralsDeVilajuigaS.aMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsMalaysiaSdnBhdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsThailandLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_InterstateBloodBankIncorporatedBioBloodComponentsIncorporatedAndPlasmaBiologicalServicesLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_InterstateBloodBankIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_BioBloodComponentsIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_PlasmaBiologicalServicesLimitedLiabilityCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_KiroGrifolsS.lMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_AraclonBiotechS.lMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_ProgenikaBiopharmaSaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_HologicAcquisitionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_SignificantInvestmentsInSubsidiariesAxis=grfs_GrifolsDiagnosticsSolutionsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |